Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Pharmacokinetics and Pharmacodynamics

• Publication date

  2011-11-19

• Fields of study

  Medicine, Computer Science

• Identifiers
  DOI 10.1007/s10928-011-9228-yPMID 22101761
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design evaluation and optimisation in crossover pharmacokinetic studies analysed by nonlinear mixed effects models

  2012cited by this paper
• Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0

  2010cited by this paper
• Target-mediated drug disposition model for drugs that bind to more than one target

  2010cited by this paper
• Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic–pharmacodynamic modeling of biologics

  2009cited by this paper
• Approximations of the target-mediated drug disposition model and identifiability of model parameters

  2008cited by this paper
• Mixed‐Effects Models

  2007cited by this paper
• A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples

  2007cited by this paper
• Maximum likelihood estimation in nonlinear mixed effects models

  2005cited by this paper
• Monte Carlo Parametric Expectation Maximization (MC-PEM) Method for Analyzing Population Pharmacokinetic/Pharmacodynamic Data

  2004cited by this paper
• General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

  2001cited by this paper
• WinBUGS - A Bayesian modelling framework: Concepts, structure, and extensibility

  2000cited by this paper

• ADPO: automatic-differentiation-assisted parametric optimization

  2025cites this paper
• Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice

  2024cites this paper
• Population Pharmacokinetics of the Novel Adenosine A2A Antagonist/Inverse Agonist KW‐6356 and Its Active Metabolite Following Single and Multiple Oral Administration in Healthy Individuals and Patients with Parkinson's Disease

  2024cites this paper
• A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy

  2024cites this paper
• Population Pharmacokinetic Modelling of the Complex Release Kinetics of Octreotide LAR: Defining Sub-Populations by Cluster Analysis

  2021cites this paper
• Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors

  2021cites this paper
• Comparing the performance of first-order conditional estimation (FOCE) and different expectation–maximization (EM) methods in NONMEM: real data experience with complex nonlinear parent-metabolite pharmacokinetic model

  2021cites this paper
• A population K-PD model analysis of long-term testosterone inhibition in prostate cancer patients undergoing intermittent androgen deprivation therapy

  2021cites this paper
• Delay differential equations based models in NONMEM

  2021cites this paper
• Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferon‐γ–Induced Protein 10, BMS‐986184, in Healthy Participants to Guide Therapeutic Dosing

  2020cites this paper
• NONMEM Tutorial Part II: Estimation Methods and Advanced Examples

  2019cites this paper
• Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab‐refractory follicular lymphoma patients in the GADOLIN phase III study

  2019cites this paper
• Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors

  2019cites this paper
• Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures.

  2019cites this paper
• Modeling Approaches to Characterize Target-Mediated Pharmacokinetics and Pharmacodynamics for Therapeutic Proteins

  2019cites this paper
• Tutorial: Numerical (NONMEM) Implementation of the Target-Mediated Drug Disposition Model

  2019cites this paper
• Evaluation of FOCEI and SAEM Estimation Methods in Population Pharmacokinetic Analysis Using NONMEM® Across Rich, Medium, and Sparse Sampling Data

  2018cites this paper
• Population pharmacokinetics–pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex

  2018cites this paper
• Mechanism-Based Approach to the Economic Evaluation of Pharmaceuticals

  2018cites this paper
• Applying a Global Sensitivity Analysis Workflow to Improve the Computational Efficiencies in Physiologically-Based Pharmacokinetic Modeling

  2018cites this paper
• Kinetic Models in Life Science — Contributions to Methods and Applications

  2017cites this paper
• Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects

  2017influential citation
• Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models

  2016cites this paper
• Sensitivity-based gradients for parameter estimation in nonlinear mixed effects models with deterministic and stochastic dynamics

  2016cites this paper
• Development and applications of physiologically-based pharmacokinetic models for population data analyses

  2015influential citation
• Modeling of safe window for percutaneous thoracic sympathectomy

  2015cites this paper
• Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy

  2015cites this paper
• Using sensitivity equations for computing gradients of the FOCE and FOCEI approximations to the population likelihood

  2015cites this paper
• Prediction of long-term treatment outcome in HCV following 24 day PEG-IFN alpha-2b therapy using population pharmacokinetic-pharmacodynamic mixture modeling and classification analysis.

  2015cites this paper
• Combining the ‘bottom up’ and ‘top down’ approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data

  2015cites this paper
• A Drug-Disease Model Describing the Effect of Oseltamivir Neuraminidase Inhibition on Influenza Virus Progression

  2015cites this paper
• Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL

  2014cites this paper
• Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach

  2014cites this paper
• Evaluation of bias, precision, robustness and runtime for estimation methods in NONMEM 7

  2014cites this paper
• Powers of the Likelihood Ratio Test and the Correlation Test Using Empirical Bayes Estimates for Various Shrinkages in Population Pharmacokinetics

  2014cites this paper
• Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development—Part 2: Introduction to Pharmacokinetic Modeling Methods

  2013cites this paper
• Comparison of Estimation Methods in NONMEM 7.2: Application to a Real Clinical Trial Dataset

  2013cites this paper
• Novel Hybrid GPU–CPU Implementation of Parallelized Monte Carlo Parametric Expectation Maximization Estimation Method for Population Pharmacokinetic Data Analysis

  2013cites this paper
• Pharmacokinetic-Pharmacodynamic Modeling of Antibacterial Drugs

  2013cites this paper
• Performance Comparison of Various Maximum Likelihood Nonlinear Mixed-Effects Estimation Methods for Dose–Response Models

  2012cites this paper